Nuclear receptor subfamily 5 group A member 2 (NR5A2) (NR5A2)

Nuclear receptor subfamily 5 group A member 2 (NR5A2), also known as Liver receptor homolog-1 (LRH-1), is a pivotal transcription factor within the nuclear receptor superfamily (UniProt: P50539). It is predominantly expressed in the liver, pancreas, and intestine, where it serves as a master regulator of bile acid biosynthesis, cholesterol homeostasis, and steroidogenesis (PubMed: 10805775). NR5A2 is also crucial for maintaining the pluripotency of embryonic stem cells and governing cell cycle progression (PubMed: 19543270). In clinical contexts, NR5A2 is strongly associated with various malignancies; it is often overexpressed in pancreatic, breast, and colorectal cancers, driving tumor proliferation and chemoresistance (PubMed: 20676377). Conversely, its role in intestinal steroidogenesis makes it a target for treating inflammatory bowel diseases (PubMed: 17603486). Pharmacological efforts focus on developing small-molecule modulators, including agonists like RJW100 for metabolic and inflammatory conditions, and antagonists for oncology applications, though most remain in the discovery or preclinical stage (PubMed: 21851345).

Other names

Liver receptor homolog-1LRH-1B1-binding factorB1FCYP7A promoter-binding factorCPFFTZ-F1 betaFTZF1

NR5A2 acts as a monomeric transcription factor that binds to specific DNA response elements to regulate gene expression. It possesses a large, hydrophobic ligand-binding pocket that can accommodate phospholipids like dilauroylphosphatidylcholine (DLPC) or synthetic small molecules. Binding of an agonist induces a conformational change that facilitates the recruitment of coactivators, whereas antagonists or inverse agonists promote the recruitment of corepressors or prevent coactivator binding, thereby modulating the transcription of downstream metabolic and proliferative genes (PubMed: 21851345, 25661151).